Terms: = Lung cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Prognosis
467 results:
1. Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.
Nagakubo Y; Hirotsu Y; Yoshino M; Amemiya K; Saito R; Kakizaki Y; Tsutsui T; Miyashita Y; Goto T; Omata M
Sci Rep; 2024 May; 14(1):12480. PubMed ID: 38816489
[TBL] [Abstract] [Full Text] [Related]
2. Role of antihypertensive medicines in prostate cancer: a systematic review.
Iheanacho CO; Enechukwu OH
BMC Cancer; 2024 Apr; 24(1):542. PubMed ID: 38684963
[TBL] [Abstract] [Full Text] [Related]
3. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
Mei W; Wang XM; Liu RA; Xiong W; Zhang YP
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr; 42(4):258-267. PubMed ID: 38677988
[No Abstract] [Full Text] [Related]
4. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
5. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
[No Abstract] [Full Text] [Related]
7. High CASC expression predicts poor prognosis of lung cancer: A systematic review with meta-analysis.
Han H; Huang H; Chen AP; Tang Y; Huang X; Chen C
PLoS One; 2024; 19(4):e0292726. PubMed ID: 38573879
[TBL] [Abstract] [Full Text] [Related]
8. Mesothelin promotes brain metastasis of non-small cell lung cancer by activating met.
Xia S; Duan W; Xu M; Li M; Tang M; Wei S; Lin M; Li E; Liu W; Wang Q
J Exp Clin Cancer Res; 2024 Apr; 43(1):103. PubMed ID: 38570866
[TBL] [Abstract] [Full Text] [Related]
9. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell lung cancer (NSCLC) Harbouring metex14 Skipping in the UK.
Batteson R; Hook E; Wheat H; Hatswell AJ; Vioix H; McLean T; Alexopoulos ST; Baijal S; Paik PK
Target Oncol; 2024 Mar; 19(2):191-201. PubMed ID: 38492157
[TBL] [Abstract] [Full Text] [Related]
10. met alterations in advanced non-small cell lung cancer.
Chagas GCL; Rangel AR; El Osta B
Curr Probl Cancer; 2024 Apr; 49():101075. PubMed ID: 38480027
[TBL] [Abstract] [Full Text] [Related]
11. Mechanism of Induction of P-gp Activity During met Induced by DEX in lung cancer Cell Line.
Liu W; Zhang X; Sunakawa H; Perera LMB; Martha L; Mizoi K; Ogihara T
J Pharm Sci; 2024 Jun; 113(6):1674-1681. PubMed ID: 38432625
[TBL] [Abstract] [Full Text] [Related]
12. 2021 WHO Classification of lung cancer: Molecular Biology Research and Radiologic-Pathologic Correlation.
Sasaki T; Kuno H; Hiyama T; Oda S; Masuoka S; Miyasaka Y; Taki T; Nagasaki Y; Ohtani-Kim SJ; Ishii G; Kaku S; Shroff GS; Kobayashi T
Radiographics; 2024 Mar; 44(3):e230136. PubMed ID: 38358935
[TBL] [Abstract] [Full Text] [Related]
13. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.
Gu Z; Huang P; Zhao J; Luo C; Liao L; Liu A; Huang L
Int J Cancer; 2024 Jun; 154(11):1979-1986. PubMed ID: 38353428
[TBL] [Abstract] [Full Text] [Related]
14. DLX1 acts as a novel prognostic biomarker involved in immune cell infiltration and tumor progression in lung adenocarcinoma.
Du Y; Li H; Wang Y; He Y; Li G
PeerJ; 2024; 12():e16823. PubMed ID: 38317839
[TBL] [Abstract] [Full Text] [Related]
15. Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small Cell lung cancer.
Kanasaki H; Ozawa Y; Nakamura N; Nagasaki K; Matsuyama W; Akahori D; Niwa M; Ogasawara T; Sato J
Anticancer Res; 2024 Feb; 44(2):723-730. PubMed ID: 38307579
[TBL] [Abstract] [Full Text] [Related]
16. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
17. The role of α7-nAChR-mediated PI3K/AKT pathway in lung cancer induced by nicotine.
He Z; Xu Y; Rao Z; Zhang Z; Zhou J; Zhou T; Wang H
Sci Total Environ; 2024 Feb; 912():169604. PubMed ID: 38157907
[TBL] [Abstract] [Full Text] [Related]
18. Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis.
Shimizu T; Inoue E; Ohkuma R; Kobayashi S; Tsunoda T; Wada S
Front Immunol; 2023; 14():1308381. PubMed ID: 38115995
[TBL] [Abstract] [Full Text] [Related]
19. Allergic sensitization does not influence advancement or survival in oral cancer.
Kakabas L; Piersiala K; Kolev A; Kumlien Georén S; Cardell LO
Sci Rep; 2023 Dec; 13(1):21696. PubMed ID: 38066212
[TBL] [Abstract] [Full Text] [Related]
20. Incidence and mortality of second primary malignancies after lymphoma: a population-based analysis.
Liu Y; Chu Y; Liu J; Ge X; Ding M; Li P; Liu F; Zhou X; Wang X
Ann Med; 2023; 55(2):2282652. PubMed ID: 38010751
[TBL] [Abstract] [Full Text] [Related]
[Next]
